Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications Cumbie BC; Hermayer KLVasc Health Risk Manag 2007[]; 3 (6): 823-32Microvascular complications characterized by retinopathy, nephropathy, and neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay for preventing progression of these complications; however, such control is not easily achieved. Currently, alternative adjunctive approaches to treating and preventing microvascular damage are being undertaken by targeting the molecular pathogenesis of diabetic complications. This review summarizes the specific pathogenic mechanisms of microvascular complications for which clinical therapies have been developed, including the polyol pathway, advanced glycation end products, protein kinase c, vascular epithelium growth factor, and the superoxide pathway. The review further focuses on therapies for these targets that are currently available or are undergoing late-stage clinical trials.|Aldehyde Reductase/antagonists & inhibitors[MESH]|Antioxidants/pharmacology/therapeutic use[MESH]|Diabetes Complications/*physiopathology/*prevention & control[MESH]|Enzyme Inhibitors/pharmacology/therapeutic use[MESH]|Glycation End Products, Advanced/antagonists & inhibitors[MESH]|Humans[MESH]|Protein Kinase C/antagonists & inhibitors[MESH]|Reactive Oxygen Species[MESH]|Vascular Endothelial Growth Factors/antagonists & inhibitors[MESH] |
